Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19

A method for treating a B-cell malignancy in a human patient, the method comprising:

• (i) subjecting a human patient having a B-cell malignancy to a lymphodepletion treatment;
• and
• (ii) administering to the human patient a population of genetically engineered T cells after step (i), wherein the population of genetically engineered T cells comprising T cells that comprise:
• (a) a disrupted T cell receptor alpha constant (TRAC) gene,
• (b) a nucleic acid coding for a chimeric antigen receptor (CAR) that binds CD19, wherein the CAR comprises an anti-CD19 single chain variable fragment (scFv) that comprises a heavy chain variable region set forth in SEQ ID NO:
• 51, and a light chain variable region set forth in SEQ ID NO:
• 52, and wherein the nucleic acid is inserted in the disrupted TRAC gene, and
• (c) a disrupted beta 2-microglobulin (β2M) gene;
• wherein the population of genetically engineered T cells is administered to the human patient at a dose of about 1×107 to about 1×109 CAR+ T cells;
• and wherein the population of genetically engineered T cells is allogeneic to the human patient.